Maxwell Biosciences hnology company developing a novel drug platform of synthetic, peptide‑mimetic small molecules called CLAROMER®, designed to replicate and enhance the body’s innate immune peptides. Their lead candidates target viruses, bacteria, fungi and biofilms via a mechanism of pathogen‑membrane disruption, while reportedly preserving beneficial human microbiota. Maxwell has entered multiple Cooperative Research & Development Agreements (CRADAs) with U.S. military and government agencies—including a $3 million award from the Medical Technology Enterprise Consortium (MTEC) and a partnership with the U.S. Army Institute of Surgical Research (USAISR) in 2025. The company remains in the pre‑clinical stage, with human trials planned (2025–26) and an aim to expand into health‑span and aging applications.